The National Medical Products Administration has granted marketing registration approval to Aimei Vaccine Group's innovative serum-free rabies vaccine. Additionally, the group's wholly-owned subsidiary, Aimei Rongyu Biopharmaceutical, has secured the necessary production license. This vaccine is poised to be the first serum-free rabies vaccine available on the market, promising heightened safety and a substantial reduction in adverse reaction risks. Given China's status as the world's largest rabies vaccine market, projections indicate a market size of 14.8 billion yuan by 2030. As the second-largest rabies vaccine supplier globally, Aimei Vaccine Group has successfully established international-standard workshops and completed large-scale production verification. With this approval, the vaccine is set for prompt market introduction, potentially leading to a significant boost in the company's performance.